The Peter Attia Drive

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into the liver and its central role in metabolic health. He explains why the liver can serve as a "canary in the coal mine" for metabolic dysfunction and explores how insulin resistance, visceral fat, alcohol consumption, genetics, and hormones contribute to liver disease, along with how increasing muscle mass can benefit liver health. Peter provides a framework for understanding the progression of liver disease, highlighting which stages are reversible and why early detection matters. He explains why normal liver enzymes can provide false reassurance, which labs he uses to assess liver health, and the tools available for detecting fibrosis and more advanced disease. Peter then breaks down the interventions that can meaningfully improve liver health once risk or disease is identified, ranging from diet and exercise to GLP-1–based therapies and other medications. Finally, he examines popular claims around liver "detoxification" and supplements, separating what is supported by evidence from what is unlikely to meaningfully improve liver health.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #88 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Why the liver is the "canary in the coal mine" for metabolic dysfunction, and an overview of what the liver does [2:00];
The relationship between the liver and blood sugar control [6:30];
A framework for understanding how metabolic disease affects the liver [9:15];
Chronic caloric surplus and insulin resistance as drivers of liver disease [11:00];
Liver diseases that result from metabolic dysfunction and the difference between steatosis and fibrosis [15:15];
How visceral fat affects liver health [20:00];
The importance of lifestyle interventions for liver and metabolic health: resistance training, not drinking calories, and the impact of fructose [22:00];
Why alcohol-associated liver disease is more common than we give it credit for [26:30];
Genetic and hormonal risks for liver disease [31:45];
Labs that objectively measure liver health and the FIB-4 score [35:30];
FibroScan: non-invasive imaging of the liver [44:30];
The resiliency of the liver: an organ that can heal itself [47:00];
Fibrosis staging and its impact on mortality and cancer risk [49:15];
Interventions for someone with MASLD: weight loss and GLP-1s [52:00];
Other medications used to treat metabolic liver disease [57:00];
The role of exercise in treating metabolic liver disease: caloric deficit and building muscle [59:45];
The myth of liver detoxes and cleanses, and a few supplements that may benefit the liver [1:01:15];
A practical summary: how to assess your risk and the levers that reverse the disease [1:08:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness.
We discuss:
Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45];
A short primer on the different classes of drugs used in psychiatry [12:45];
Evaluation of a patient with bipolar disorder [26:00];
An evolutionary perspective on depression [33:30];
Changes in the modern world triggering mental health problems [41:00];
An evolutionary perspective on insomnia [48:15];
Peter's window analogy to understand distress tolerance and irritability [49:45];
The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30];
The effect of estradiol on neurotransmitters in the brain [58:15];
Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00];
The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30];
Treatment of postpartum depression [1:18:00];
Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00];
The link between hyperarousal and chronically elevated cortisol [1:39:30];
A case where the menopause transition uncovers bipolar disorder [1:44:15];
Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15];
Case study: an Alzheimer's patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15];
Peter's experience with psychedelics, and the myth that estrogen is bad for men [2:00:30];
The therapeutic potential of psychedelics in psychiatry [2:11:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence.
We discuss:
What peptides are and why they must be evaluated individually [3:15];
A five-question framework for evaluating peptides and other drugs [5:30];
A three-tier system for classifying the scientific evidence behind peptides [10:00];
Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00];
Why BPC-157's expanding claims do not indicate a broad mechanism [20:45];
CJC-1295: biological activity versus meaningful clinical benefit [23:30];
Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30];
The placebo effect, and the importance of controlled trials for evaluating peptides [31:00];
What FDA approval provides when evaluating peptide safety and effectiveness [34:45];
Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30];
Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45];
Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00];
The promise of peptide science, and the risks of the gray-market wellness industry [46:30];
Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, "fluffy" LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test.
We discuss:
How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30];
How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15];
How NMR spectroscopy measures lipoprotein particle size and concentration [20:30];
Why LDL particle number matters more than particle size, and why large, "fluffy" LDL is not benign [28:45];
Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30];
How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30];
Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15];
The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45];
The analytical efficiency of NMR testing and the data-driven development of the Metabolic
Vulnerability Index (MVX) [1:16:00];
GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45];
Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00];
What MVX can tell us about longevity and mortality [1:44:15];
How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30];
Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00];
ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30];
Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00];
The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies.
We discuss:
The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30];
Why basic research and nature's biological innovations are the foundation of medical progress [10:45];
The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15];
From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00];
From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00];
The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15];
The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30];
Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube